• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非亲缘供者干细胞移植的非人类白细胞抗原屏障

Non-HLA barriers to unrelated donor stem cell transplantation.

作者信息

Kollman C, Weis T, Switzer G E, Halet M, Kitajima D, Hegland J, Confer D L

机构信息

National Marrow Donor Program, Minneapolis, MN 55413, USA.

出版信息

Bone Marrow Transplant. 2001 Mar;27(6):581-7. doi: 10.1038/sj.bmt.1702845.

DOI:10.1038/sj.bmt.1702845
PMID:11319586
Abstract

A prospective survey involving 544 searches of the US National Marrow Donor Program (NMDP) Registry was conducted to identify reasons why many patients who have apparent HLA-matched donors do not proceed to transplant. Coordinators at NMDP transplant centers, patients and referring physicians were surveyed shortly after the initial search, and follow-up surveys were sent to the coordinators as the search was ongoing. The death of the patient, worsening of the patient's medical condition and length of the search process were the most commonly cited barriers to transplantation. Other times a decision was made not to transplant through the NMDP due to the use of a donor from another source, a preference for chemotherapy or immunotherapy, hesitancy on the part of the transplant physician or patient, or because the patient did not require a transplant. Responses differed between U.S. and international cases. An unrelated donor outside the NMDP was the most common reason cited by international coordinators (46%), whereas the death of the patient was the most common reason among US coordinators (13%). The death of the patient was the second most common reason cited by international coordinators at 9%. Financial problems were listed by 41% of US coordinators as a potential barrier at the time of initial search, but only 5% indicated this as an actual barrier on a follow-up survey. Finances were cited as the most important reason 3% of the time overall, and 6% for African Americans and Asian/Pacific Islanders.

摘要

开展了一项前瞻性调查,涉及对美国国家骨髓捐献者计划(NMDP)登记处的544次检索,以确定许多有明显HLA匹配捐献者的患者未进行移植的原因。在首次检索后不久,对NMDP移植中心的协调员、患者及转诊医生进行了调查,并在检索进行期间向协调员发送了后续调查问卷。患者死亡、病情恶化以及检索过程的时长是最常被提及的移植障碍。其他时候,由于使用了来自其他来源的捐献者、倾向于化疗或免疫疗法、移植医生或患者犹豫不决,或者患者不需要移植,故而决定不通过NMDP进行移植。美国和国际案例的回答有所不同。NMDP之外的无关捐献者是国际协调员提及的最常见原因(46%),而患者死亡是美国协调员中最常见的原因(13%)。患者死亡是国际协调员提及的第二常见原因,为9%。41%的美国协调员在首次检索时将经济问题列为潜在障碍,但在后续调查中只有5%表示这是实际障碍。总体而言,3%的情况下经济因素被视为最重要的原因,非裔美国人和亚裔/太平洋岛民中这一比例为6%。

相似文献

1
Non-HLA barriers to unrelated donor stem cell transplantation.非亲缘供者干细胞移植的非人类白细胞抗原屏障
Bone Marrow Transplant. 2001 Mar;27(6):581-7. doi: 10.1038/sj.bmt.1702845.
2
The National Marrow Donor Program: improving access to hematopoietic cell transplantation.国家骨髓捐献项目:改善造血细胞移植的可及性。
Clin Transpl. 2011:55-62.
3
The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation.美国国家骨髓捐赠项目在非亲缘供者造血细胞移植中的作用。
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S3-S5. doi: 10.1038/bmt.2008.102.
4
Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?在基因上HLA - A、- B和 - DRB1相同的无关志愿者中,应选择哪一位作为造血干细胞移植的供者?
Biol Blood Marrow Transplant. 2004 Feb;10(2):128-34. doi: 10.1016/j.bbmt.2003.10.001.
5
Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program.异体造血细胞移植的紧迫时机:全国骨髓捐献者计划组织相容性咨询组协助进行的移植医生和非亲缘供者检索协调员的全国性调查。
Biol Blood Marrow Transplant. 2019 Dec;25(12):2501-2506. doi: 10.1016/j.bbmt.2019.08.002. Epub 2019 Aug 13.
6
Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.源自脐带血、骨髓或外周血的造血干细胞移植:异质性风险人群的单中心配对分析
Klin Padiatr. 2004 Nov-Dec;216(6):356-63. doi: 10.1055/s-2004-832357.
7
The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation.国家骨髓捐赠计划20年非血缘供者造血细胞移植。
Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):2-7. doi: 10.1016/j.bbmt.2008.05.017.
8
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
9
Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program.美国国家骨髓捐赠项目推动下的20年小儿急性白血病非亲属供者骨髓移植
Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22. doi: 10.1016/j.bbmt.2008.05.019.
10
Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies.血红蛋白病造血干细胞移植无关供者的可及性
Bone Marrow Transplant. 2003 Apr;31(7):547-50. doi: 10.1038/sj.bmt.1703887.

引用本文的文献

1
Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.医疗保险受益人群中急性髓细胞白血病患者接受异基因造血细胞移植的利用趋势和未满足需求估计。
Transplant Cell Ther. 2022 Dec;28(12):852-858. doi: 10.1016/j.jtct.2022.09.015. Epub 2022 Sep 25.
2
Multimedia resources to support the recruitment of committed hematopoietic stem cell donors: Perspectives of the most-needed donors.支持招募造血干细胞志愿捐献者的多媒体资源:最急需捐献者的观点
Transfusion. 2021 Jan;61(1):274-285. doi: 10.1111/trf.16186. Epub 2020 Dec 2.
3
Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.
美国成人造血细胞移植的障碍:一项以年龄为重点的系统评价
Biol Blood Marrow Transplant. 2020 Dec;26(12):2335-2345. doi: 10.1016/j.bbmt.2020.09.013. Epub 2020 Sep 20.
4
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.采用包括移植后环磷酰胺在内的强化移植物抗宿主病预防方案的单倍体相合骨髓移植治疗重型再生障碍性贫血。
Blood Adv. 2020 Apr 28;4(8):1770-1779. doi: 10.1182/bloodadvances.2020001729.
5
Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.采用大剂量移植后环磷酰胺的替代供体移植治疗难治性重型再生障碍性贫血
Biol Blood Marrow Transplant. 2017 Mar;23(3):498-504. doi: 10.1016/j.bbmt.2016.12.628. Epub 2016 Dec 21.
6
Giving blood and enrolling on the stem cell donor registry: ranking of obstacles and motives in Switzerland.献血和登记成为干细胞捐献者:瑞士的障碍和动机排名。
Transfus Med Hemother. 2014 Jul;41(4):264-72. doi: 10.1159/000365457. Epub 2014 Jul 4.
7
Racial disparities in hematopoietic cell transplantation in the United States.美国造血细胞移植中的种族差异。
Bone Marrow Transplant. 2012 Nov;47(11):1385-90. doi: 10.1038/bmt.2011.214. Epub 2011 Nov 7.
8
Access to hematopoietic cell transplantation in the United States.美国的造血细胞移植途径。
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5. doi: 10.1016/j.bbmt.2009.12.529. Epub 2009 Dec 28.
9
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.高剂量方案的异基因造血细胞移植成本。
Biol Blood Marrow Transplant. 2008 Feb;14(2):197-207. doi: 10.1016/j.bbmt.2007.10.010.